Work

p53 mutational status, but not immunohistochemical staining (IHC), is associated with a clinical response of the primary tumor in women receiving neoadjuvant docetaxel-capecitabine chemotherapy for locally advanced breast cancer.

Year: 2009

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs-6047

Authors: JS Ross, CM Perou, N Aki, N Patten, L Wu, EF McKenna, H Lawrence, M Royce, E Avisar, S Gluck

Institutions: Albany Medical College, University of North Carolina at Chapel Hill, University of New Mexico, University of Miami

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1996113040

Cites:

Cited by: 1

Related to: 10